Can atypical antipsychotic augmentation reduce subsequent treatment failure more effectively among depressed patients with a higher degree of treatment resistance a meta-analysis of randomized controlled trials

International Journal of Neuropsychopharmacology

Volumn 18, Issue 8, 2015, Pages 1-10

  Wang, Hee Ryung ^a   Woo, Young Sup ^a   Ahn, Hyeong Sik ^b   Ahn, Il Min ^c   Kim, Hyun Jung ^c   Bahk, Won Myong ^a  

^a The Catholic University of Korea   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c BROWN UNIVERSITY   (United States)

Author keywords

Atypical Antipsychotics; Augmentation; Major Depressive Disorder; Treatment Resistance

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BLONANSERIN; CLOZAPINE; ILOPERIDONE; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE; ZOTEPINE;

ADD ON THERAPY; DRUG EFFICACY; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG POTENTIATION;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG SYNERGISM; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE;

EID: 84931271037     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyv023     Document Type: Review

References (43)

1. Altamura AC, Montresor C, Salvadori D, Mundo E (2004) Does comorbid subthreshold anxiety affect clinical presentation and treatment response in depression? A preliminary 12-month naturalistic study. Int J Neuropsychop 7:481-487
2. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M (2009) Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, doubleblind study. J Clin Psychiatry 70:540-549
3. Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M (2014) Role of lithium augmentation in the management of major depressive disorder. CNS Drugs 28:331-342
4. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A (2007) The efficacy and safety of ari-piprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:843-853
5. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN (2009) Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 14:197-206
6. Bschor T, Canata B, Muller-Oerlinghausen B, Bauer M (2001) Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord 64:261-265
7. Carvalho AF, Berk M, Hyphantis TN, McIntyre RS (2014) The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom 83:70-88
8. Chen J, Gao K, Kemp DE (2011) Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry 24:10-17
9. Choi E, Zmarlicka M, Ehret MJ (2012) Vilazodone: a novel antidepressant. Am J Health Syst Pharm 69:1551-1557
10. Citrome L (2013) Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 67:1089-1104
11. El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H (2010) Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychop 13:917-932
12. Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53:649-659
13. Fond G, Loundou A, Rabu C, Macgregor A, Lancon C, Brittner M, Micoulaud-Franchi JA, Richieri R, Courtet P, Abbar M, Roger M, Leboyer M, Boyer L (2014) Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl) 231:3663-3676
14. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J (2010) Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303:47-53
15. Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J (2008) A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 23:269-275
16. Garnock-Jones KP, McCormack PL (2010) Escitalopram: a review of its use in the management of major depressive disorder in adults. CNS Drugs 24:769-796
17. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62
18. Higgins JPT, Green S (2008) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. Oxford: The Cochrane Collaboration
19. Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, Kinoshita T, Koyama T (2013) Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebocontrolled study (ADMIRE study). J Affect Disord 151:899-905
20. Karp JF, Scott J, Houck P, Reynolds CF , Kupfer DJ, Frank E (2005) Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry 66:591-597
21. Kato M, Chang CM (2013) Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression. CNS Drugs 27(Supp 1):S11-19
22. Komossa K, Depping AD, Gaudchau A, Kissling W, Leucht S (2010) Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev. Advance online publication. Retrieved 8 Dec 2010. doi: 10.1002/14651858.CD008121.pub2
23. Lin CH, Lin SH, Jang FL (2011) Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. J Clin Psychopharmacol 31:563-568
24. Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, Gharabawi-Garibaldi GM (2007) Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 147:593-602
25. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM (2008) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28:156-165
26. McIntyre RS, Filteau MJ, Martin L, Patry S, Carvalho A, Cha DS, Barakat M, Miguelez M (2014) Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord 156:1-7
27. McNamara RK, Strimpfel J, Jandacek R, Rider T, Tso P, Welge JA, Strawn JR, Delbello MP (2014) Detection and Treatment of Long-Chain Omega-3 Fatty Acid Deficiency in Adolescents with SSRI-Resistant Major Depressive Disorder. PharmaNutrition 2:38-46
28. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389
29. Nelson JC, Papakostas GI (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psych 166:980-991
30. Nichols AI, Tourian KA, Tse SY, Paul J (2010) Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor. Expert Opin Drug Metab Toxicol 6:1565-1574
31. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G, Lebowitz B, Shores-Wilson K, Rush AJ (2006) A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR D report. Am J Psych 163:1519-1530
32. Pae CU, Patkar AA, Gilmer W, Holtzman N, Thommi SB, Ghaemi SN (2012) Predictors of response to ziprasidone: results from a 6-week randomized double-blind, placebo-controlled trial for acute depressive mixed state. Pharmacopsychiatry 45:152-155
33. Papakostas GI, Shelton RC, Smith J, Fava M (2007) Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a metaanalysis. J Clin Psychiatry 68:826-831
34. Patkar A, Gilmer W, Pae CU, Vohringer PA, Ziffra M, Pirok E, Mulligan M, Filkowski MM, Whitham EA, Holtzman NS, Thommi SB, Logvinenko T, Loebel A, Masand P, Ghaemi SN (2012) A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLOS ONE 7:e34757
35. Rocha FL, Fuzikawa C, Riera R, Hara C (2012) Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis. J Clin Psychopharmacol 32:278-281
36. Ruhe HG, Huyser J, Swinkels JA, Schene AH (2006) Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 67:1836-1855
37. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR D report. Am J Psych 163:1905-1917
38. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013) Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLOS Med 10:e1001403
39. Thase ME, Rush AJ (1997) When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry 58(Supp 13):23-29
40. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, Watson SB, Dube S (2007) A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 68:224-236
41. Turner P, Kantaria R, Young AH (2014) A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: a European perspective. J Psychopharmacol 28:85-98
42. Vieta E, Colom F (2011) Therapeutic options in treatment-resistant depression. Ann Med 43:512-530
43. Wright BM, Eiland EH , Lorenz R (2013) Augmentation with atypical antipsychotics for depression: a review of evidencebased support from the medical literature. Pharmacotherapy 33:344-359